Merck to participate in Medicare negotiations process 'under protest,' following at least three others
Merck said on Thursday that it will participate “under protest” in the first round of price negotiations with the Centers for Medicare and Medicaid Services for its type 2 diabetes treatment Januvia (sitagliptin).
The company is the fourth to announce that it will agree to the Inflation Reduction Act’s Medicare negotiations process ahead of an Oct. 1 deadline for participation, following Bristol Myers Squibb, AstraZeneca and Boehringer Ingelheim. More are likely to follow, as those who do not comply will face a steep tax or risk losing out on Medicare and Medicaid coverage altogether. The IRS has published proposed guidance on how taxpayers will report liability for such excise taxes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.